Evidence map›Paper›PMID 35335892›Full record

ArticlePharmaceutics2022

Creating Acceptable Tablets 3D (CAT 3D): A Feasibility Study to Evaluate the Acceptability of 3D Printed Tablets in Children and Young People.

Louise Bracken, Rober Habashy, Emma McDonough, Fiona Wilson, Joanne Shakeshaft, Udeme Ohia, Tamar Garcia-Sorribes, Abdullah Isreb, Mohamed A Alhnan, Matthew Peak

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Louise BrackenPaediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.ORCID 0000-0002-9632-2252
Rober HabashySchool of Medicine and Biomedical Science, University of Central Lancashire, Preston PR1 2HE, UK.
Emma McDonoughPaediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.
Fiona WilsonNIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.
Joanne ShakeshaftPaediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.
Udeme OhiaNIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.
Tamar Garcia-SorribesSchool of Medicine and Biomedical Science, University of Central Lancashire, Preston PR1 2HE, UK.
Abdullah IsrebSchool of Medicine and Biomedical Science, University of Central Lancashire, Preston PR1 2HE, UK.
Mohamed A AlhnanCentre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College, London SE1 9NH, UK.
Matthew PeakPaediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool L12 2AP, UK.ORCID 0000-0003-1909-3211
Alder Hey Children's NHS Foundation Trust · GBUniversity of Lancashire · GBKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3D printing (3DP) has been proposed as a novel approach for personalising dosage forms for children and young people (CYP). Owing to its low cost and the lack of need for finishing steps, fused deposing modelling (FDM) 3DP has been heavily researched in solid dosage forms (SDFs) manufacturing. However, the swallowability and overall acceptability of 3D printed dosage forms are yet to be established. This work is the first to evaluate the acceptability of different sized 3D printed placebo SDFs in CYP (aged 4-12 years). All participants had previously participated in a feasibility study (CAT study) that assessed the swallowability and acceptability of different sized GMP manufactured placebo conventional film-coated tablets, and therefore only attempted to swallow one 3D printed tablet. The participants assessed the swallowability, acceptability, mouthfeel, volume of water consumed, and taste of the sample using a 5-point hedonic facial scale on a participant questionnaire. A total of 30 participants were recruited, 87% of whom successfully swallowed the 3D printed tablet that they attempted to take. Attributes of the 3D printed tablets were scored as acceptable by the following percentage of participants-swallowability (80%), mouthfeel/texture (87%), the volume of water consumed (80%), taste (93%), and overall acceptability (83%). Overall, 77% of children reported they would be happy to take the tablet every day if it was a medicine. Participants were also asked which tablets felt better in the mouth-the film-coated tablets or the 3D printed tablets, and the most popular response (43%) was that both were acceptable. This study shows that FDM-based 3D printed SDFs may be a suitable dosage form for children aged 4-12 years. The results from this feasibility study will be used to inform a larger, definitive study looking at the acceptability of 3D printed tablets in children.

Indexed as

additive manufacturingage-appropriatepatient-specificpersonalised medicinepoint-of-care manufacturing

Identifiers

PMID35335892
PMCPMC8954179
OpenAlexW4214741598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.